Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Man Group PLC : Form 8.3 - Bluefield Solar Income Fund Ltd
-
SCHMID Group Secures Major Order for Wet-Process Production Equipment Supporting AI- and HPC-Infrastructure
-
Man Group PLC : Form 8.3 - JTC Plc
-
NOTICE TO DISREGARD -- Smartplay International, Inc
-
Man Group PLC : Form 8.3 - LondonMetric Property Plc
-
Volatus Aerospace Executes Contract to Develop and Commercialize Heavy-Lift Offshore Cargo Drone Deliveries for Wind Turbine Operations
-
Virtuix to Attend the 38th Annual Roth Conference
-
ModelOp’s 2026 AI Governance Benchmark Report Shows Explosion of Enterprise AI Use Cases as Agentic AI Adoption Surges But Value Still Lags
-
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
-
Dynacor Provides Expansion Update Including Steady Progress in Senegal and Ecuador
-
Kaixin Holdings Announces Share Consolidation
-
Cineplex Reports February Box Office Results
-
DEEP SEA MINERALS CORP. JOINS THE NATIONAL OCEAN INDUSTRIES ASSOCIATION (NOIA)
-
AiM Medical Robotics adds surgical robotics pioneer, Dr. Yulun Wang, to its world-class Board
-
Ocean Power Technologies, Inc. Pre Releases Third Quarter Fiscal 2026 Results
-
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
-
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
-
Stardust Power Announces Year End 2025 Earnings Release Date, Conference Call
-
Telesat schedules fourth quarter and full year 2025 earnings conference call for March 17, 2026
-
AI Adoption in Corporate Legal Departments Doubles According to The General Counsel Report
-
FirstService Corporation Announces Upcoming Meeting and Financial Reporting Dates
-
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
-
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
-
Press release - Progress in AFL’s initiatives towards 0% risk-weighting for its debt securities to support the financing of French local governments
-
Annual General Meeting 2026 – GN Store Nord A/S
-
Mink Intersects 7.1 Meters of 0.44% Ni, 0.28% Cu, 0.06% Co in Massive Sulphide at Warren Property
-
Industry Leaders Applaud tpay’s MEFFYS 2026 Win in Payment & Commerce
-
Industry Leaders Applaud tpay’s MEFFYS 2026 Win in Payment & Commerce
-
Serve Robotics and White Castle Launch Autonomous Delivery via Uber Eats
-
Dimensional Fund Advisors Ltd. : Form 8.3 - JUST GROUP PLC - Ordinary Shares
-
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
-
Calian VENTURES and Tessellate Robotics Advance Autonomous Navigation for Arctic Defence
-
Broadwind Announces Fourth Quarter and Full-Year 2025 Results
-
Serve Robotics Announces Fourth Quarter and Full Year 2025 Results
-
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
-
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
-
Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
-
H&R Block Canada's Free Tax Filing Program Marks 10 Years of Hands-On Individualized Tax Expert Support for Vulnerable Canadians
-
Sono-Tek Announces $820K Order for Diagnostic Medical Device Coating Systems
-
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
-
Beyond Air to Participate in the 38th Annual Roth Conference in March
-
Rislone Wins Prestigious AutoZone Mexico WITTDTJR Award
-
GT Biopharma to Participate in the 38th Annual Roth Conference
-
UREVO Launched "Train Hard, Recover Smart" Campaign to Redefine Smart Recovery
-
Next Hydrogen Secures Contracts Totaling $3.75 Million for Specialized Nuclear Application
-
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Dise
-
Lighter. Cheaper. Funner. Pub Light Is Here.
-
Xanadu and ETRI Partner to Accelerate Fault-Tolerant Quantum Algorithm Design using PennyLane
-
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorder
-
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
